Fig. 4From: UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATEEffects of empagliflozin versus placebo on the primary outcome of EMPA-KIDNEY, by baseline eGFR (post-hoc analysis). Post-hoc analysis of unpublished data from EMPA-KIDNEYBack to article page